UnitedHealth Group (UNH) Earns Buy Rating from Piper Jaffray Companies

Piper Jaffray Companies restated their buy rating on shares of UnitedHealth Group (NYSE:UNH) in a research note issued to investors on Wednesday morning. They currently have a $259.00 target price on the healthcare conglomerate’s stock.

A number of other brokerages also recently weighed in on UNH. Zacks Investment Research downgraded UnitedHealth Group from a buy rating to a hold rating in a research note on Tuesday, October 10th. Cantor Fitzgerald restated a buy rating and issued a $225.00 target price on shares of UnitedHealth Group in a research note on Monday, November 27th. ValuEngine downgraded UnitedHealth Group from a buy rating to a hold rating in a research note on Thursday, October 5th. Jefferies Group restated a buy rating and issued a $248.00 target price on shares of UnitedHealth Group in a research note on Friday, December 1st. Finally, Credit Suisse Group started coverage on UnitedHealth Group in a research note on Thursday, November 2nd. They issued an outperform rating and a $233.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and twenty-six have given a buy rating to the stock. UnitedHealth Group presently has a consensus rating of Buy and an average target price of $243.22.

UnitedHealth Group (UNH) opened at $243.35 on Wednesday. UnitedHealth Group has a 12 month low of $156.49 and a 12 month high of $244.35. The firm has a market capitalization of $235,822.70, a P/E ratio of 24.14, a PEG ratio of 1.42 and a beta of 0.66. The company has a quick ratio of 0.70, a current ratio of 0.73 and a debt-to-equity ratio of 0.58.

UnitedHealth Group (NYSE:UNH) last announced its earnings results on Tuesday, January 16th. The healthcare conglomerate reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.09. UnitedHealth Group had a return on equity of 21.29% and a net margin of 5.25%. The firm had revenue of $52.06 billion for the quarter, compared to the consensus estimate of $51.57 billion. During the same quarter in the previous year, the business earned $2.11 EPS. The company’s revenue was up 9.5% compared to the same quarter last year. research analysts forecast that UnitedHealth Group will post 12.52 earnings per share for the current fiscal year.

In related news, Director Gail R. Wilensky sold 5,600 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $223.31, for a total value of $1,250,536.00. Following the transaction, the director now owns 61,137 shares in the company, valued at $13,652,503.47. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Kenneth Irwin Shine sold 457 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $211.03, for a total value of $96,440.71. The disclosure for this sale can be found here. In the last quarter, insiders sold 33,655 shares of company stock worth $7,469,083. 0.89% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of UNH. Capital International Investors raised its holdings in UnitedHealth Group by 399.3% during the 3rd quarter. Capital International Investors now owns 4,132,602 shares of the healthcare conglomerate’s stock valued at $809,370,000 after acquiring an additional 3,304,902 shares during the period. Jennison Associates LLC raised its holdings in UnitedHealth Group by 146.0% during the 3rd quarter. Jennison Associates LLC now owns 5,541,977 shares of the healthcare conglomerate’s stock valued at $1,085,396,000 after acquiring an additional 3,289,470 shares during the period. Janus Henderson Group PLC raised its holdings in UnitedHealth Group by 1,820.1% during the 2nd quarter. Janus Henderson Group PLC now owns 2,388,641 shares of the healthcare conglomerate’s stock valued at $442,896,000 after acquiring an additional 2,264,242 shares during the period. Vanguard Group Inc. raised its holdings in UnitedHealth Group by 2.5% during the 2nd quarter. Vanguard Group Inc. now owns 64,578,618 shares of the healthcare conglomerate’s stock valued at $11,974,168,000 after acquiring an additional 1,588,516 shares during the period. Finally, Parametric Portfolio Associates LLC raised its holdings in UnitedHealth Group by 77.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 3,584,134 shares of the healthcare conglomerate’s stock valued at $664,570,000 after acquiring an additional 1,562,661 shares during the period. 86.09% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/21/unitedhealth-group-unh-earns-buy-rating-from-piper-jaffray-companies.html.

About UnitedHealth Group

UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.

Analyst Recommendations for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply